Independent Advisor Alliance Purchases 9,522 Shares of Edwards Lifesciences Corporation $EW

Independent Advisor Alliance grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 114.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,827 shares of the medical research company’s stock after acquiring an additional 9,522 shares during the quarter. Independent Advisor Alliance’s holdings in Edwards Lifesciences were worth $1,386,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares during the last quarter. OMERS ADMINISTRATION Corp boosted its holdings in shares of Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $300,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. This trade represents a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 57,824 shares of company stock worth $4,863,323 over the last three months. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Trading Down 0.7%

Shares of NYSE EW opened at $82.08 on Wednesday. The firm has a 50 day moving average price of $84.62 and a two-hundred day moving average price of $81.11. The stock has a market cap of $47.63 billion, a P/E ratio of 35.38, a price-to-earnings-growth ratio of 3.18 and a beta of 0.94. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on EW shares. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. Barclays reiterated an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Wells Fargo & Company set a $100.00 target price on shares of Edwards Lifesciences in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $108.00 target price on shares of Edwards Lifesciences in a research note on Friday, January 9th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $96.82.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.